Oncology catalog

Intuca 150mg Tablet contains tucatinib, a targeted tyrosine kinase inhibitor used in the treatment and management of HER2-positive breast cancer, particularly in advanced or metastatic stages. Tucatinib works by blocking specific enzymes involved in the growth and spread of cancer cells, helping to slow disease progression and improve patient outcomes. This medicine is an important part of specialist-led oncology treatment plans and may be used in combination with other anticancer therapies under close supervision. Dosage and treatment schedules are tailored by an oncologist based on the individual patient’s condition, disease stage, and response to therapy to ensure safety and effectiveness.

Tucaliv 150mg Tablet contains tucatinib, a targeted tyrosine kinase inhibitor used in the treatment and management of HER2-positive cancers. Tucatinib works by selectively blocking the activity of the HER2 protein, which is overexpressed in certain aggressive cancers such as advanced or metastatic HER2-positive breast cancer. By inhibiting this pathway, the medicine helps to slow disease progression, reduce tumour growth, and can improve patient outcomes. Tucaliv is prescribed as part of a specialist-led oncology treatment plan, often used in combination with other anticancer medicines under medical supervision. Dosage and treatment schedules are determined by the oncologist based on individual patient condition, disease stage, and response to therapy to ensure safety and effectiveness. Tucatinib is also indicated in combination with trastuzumab for certain metastatic colorectal cancers in selected patients.

Tucanat 150mg Tablet contains tucatinib, a targeted tyrosine kinase inhibitor used in the treatment and management of HER2‑positive cancers, especially advanced or metastatic HER2‑positive breast cancer. Tucatinib works by selectively blocking the activity of the human epidermal growth factor receptor‑2 (HER2) protein, which is overexpressed in certain aggressive cancers. By inhibiting this pathway, the medicine helps slow disease progression, reduce tumour growth, and improve overall patient outcomes. Tucanat is prescribed as part of a comprehensive oncology treatment plan, typically under specialist supervision. Dosage and treatment schedules are tailored by the oncologist based on individual patient condition, disease stage, and response to therapy to ensure safety and effectiveness. Key Benefits Product Info

Tucaone 150mg Tablet contains tucatinib, a targeted tyrosine kinase inhibitor used in the treatment and management of HER2‑positive cancers, especially advanced or metastatic HER2‑positive breast cancer. Tucatinib works by selectively blocking the activity of the HER2 protein, which is overexpressed in certain aggressive cancers, thereby slowing disease progression, inhibiting tumour growth, and improving overall patient outcomes when used under specialist supervision. Tucaone is often prescribed as part of a comprehensive oncology treatment plan, typically in combination with other anticancer medicines, with dosage and schedules tailored by an oncologist based on individual patient condition and response to therapy.

Tuccatinn 150mg Tablet contains tucatinib, a targeted tyrosine kinase inhibitor of the HER2 protein used in the treatment and management of HER2‑positive cancers, especially advanced or metastatic HER2‑positive breast cancer. Tucatinib works by selectively blocking the activity of the HER2 protein, helping to slow disease progression, inhibit tumour growth, and improve overall patient outcomes when used under specialist supervision. Tuccatinn is typically prescribed as part of a comprehensive oncology treatment plan, often in combination with other anticancer medicines, with dosage and schedules determined by the oncologist based on individual patient condition, disease stage, and treatment response.

Tukavo 150mg contains Tucatinib, a tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer. It is indicated especially in patients with advanced or metastatic disease who have already received prior anti-HER2-based therapies. Tukavo targets the HER2 receptor specifically, helping to slow or stop the growth of cancer cells.

Tukavo 50 mg Tablet is a prescription medicine manufactured by Zydus Lifesciences Ltd. It is used in the treatment of advanced or metastatic HER2-positive breast cancer, especially in patients who have previously been treated with other HER2-directed therapies. This medicine is commonly prescribed in combination with trastuzumab and capecitabine. Tukavo contains tucatinib, a highly selective tyrosine kinase inhibitor that targets the HER2 receptor. It works by blocking the signals that promote the growth and spread of cancer cells. Tukavo is particularly effective in patients with brain metastases, as it can cross the blood-brain barrier and help manage central nervous system involvement. At Macarius Health, we ensure timely access to Tukavo 50 mg at competitive prices, so patients can benefit from cutting-edge treatments without compromise.